Skip to main content

Servier Pharmaceuticals is a commercial-stage biotech company with current treatments for patients with acute lymphoblastic leukemia (ALL). Driven by discovery in oncology and potentially other areas of unmet medical need, we leverage Servier Group’s global portfolio and seek acquisitions, licensing deals and partnerships. We are poised to be an innovative leader serving U.S. patients and caregivers.

Servier Pharmaceuticals is a U.S. subsidiary of Servier Group, a unique international pharmaceutical group governed by a non-profit foundation. As a privately held company, we have the freedom to maintain a steady focus on the most urgent needs of patients. Our independence allows us to be more forward thinking and make sustainable choices for the long-term.

Coupled with the unique resources of Servier BioInnovation, Servier Group’s external R&D initiative, we are exploring a broad spectrum of therapeutic innovation – from the earliest research stages through commercialization.


  • 100+
  • 10+


  • David K. Lee
    Chief Executive Officer
  • Michael Bolton
    General Counsel
  • Erik Lemay
    Head of Technical Operations
  • Wendy Poage
    Head of Patient Advocacy
  • Deniz Razon
    Head of Corporate Development
  • Kelly Schlemm
    Head of Communications & Public Affairs
  • Samantha Small
    Strategy and Operations Lead
  • Latarsha Stewart
    Head of Compliance
  • Bart Van Rhijn
    Head of Finance
  • Donna Vieraitis
    Head of Human Resources
  • Mark Yunger
    Head of IT


Servier Pharmaceuticals is committed to complying with all applicable laws and regulations as well as industry codes and standards. We seek to make therapeutic progress to serve patient needs with integrity and through an effective culture of ethics and compliance.

Our Ethics & Compliance Program has been developed to be in accordance with the U.S. Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers which was published in 2003. We have also adopted and developed policies, procedures and guidelines to foster compliance with the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code on Interactions with Healthcare Professionals.

Key elements of the Servier Pharmaceuticals Ethics & Compliance Program include but are not limited to:

  • Written policies, procedures and standards of conduct
  • Designated compliance officer and compliance committee
  • Effective training, education and lines of communication
  • Internal monitoring and auditing
  • Establishing and enforcing standards through well-publicized disciplinary guidelines
  • Promptly responding to detected offenses and undertaking corrective action

California Comprehensive Compliance Program Annual Declaration


We are dedicated to supporting patients, caregivers, families and patient organizations.

Our Patient Engagement Team is available to support patients and caregivers affected by acute lymphoblastic leukemia (ALL). We can help address a variety of challenges patients and caregivers may face over the course of their journey. Our support offerings include direct patient assistance as well as referrals to third-party sources for information and support.

Our Patient Services Program focuses on offering broad-based resources and support to patients and caregivers.

Our Patient Advocacy Program recognizes the critical knowledge, resources and insights that patient organizations provide as well as their valuable work to improve the lives of individuals facing cancer.

Connect with our Patient Advocacy Team


We are committed to building a robust portfolio of treatments starting with oncology and potentially expanding to other therapeutic areas.

Advancing innovation for patients is at the heart of everything we do. Globally we devote 25 percent of our total revenue, excluding generics, to researching and developing new therapies that bring real value to patients and caregivers. Our robust pipeline includes more than a dozen oncology projects at varying stages of clinical development.



Servier Pipeline Chart - Solid Tumors

Please note that this is a comprehensive pipeline that includes both U.S. and global compounds (not all of these items are available in the U.S.).


We are dedicated to finding the best modality for the right target in the right patient at the right time.

Servier BioInnovation is a joint initiative between Servier Group R&D and Global Business Development for external innovation. Our team is responsible for increasing the group’s visibility, attracting talent and establishing research and development partnerships through targeted representation in the world’s top life science and biomedical innovation centers. We are focused on identifying new early-stage R&D opportunities and expediting business development and licensing activities in the U.S.

Our key stakeholders include world-class academic researchers, technology transfer and development offices, non-profit foundations and patient advocacy organizations, company builders, venture capitalists and strategic biotechnology and pharma partners.


  • Christian Schubert
    Director of R&D External Innovation
  • Rekha Paleyanda
    Director of U.S. Business Development and Licensing



We believe collaboration and co-creation are fundamental to driving innovation. We are actively building the kinds of alliances that bring solutions to patients’ lives and can accelerate access to therapies.

  • Allogene Therapeutics
  • Cellectis
  • Ipsen
  • Novartis
  • Pieris Targeted Therapeutics
  • Precision Biosciences
  • Symphogen
  • Taiho Pharma


Servier Group is a unique international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes, France. The group has a presence in 149 countries and 21,700 employees worldwide.

Learn more about Servier Group


Coronavirus : Adapting our Approach to Continue to Serve our Patients
03/ 19 / 2020

Press Release

Servier Showcases Robust Presence at ASH 2019
12 / 04 / 2019

Press Release

Servier Acquires Product from CTI BioPharma, Strengthening the Servier Oncology Portfolio
10 / 01 / 2019

Press Release


Work at Servier Pharmaceuticals and experience the freedom to innovate.

As the U.S. subsidiary of Servier Group, we have the resources and network of an established global pharmaceutical company while operating with the nimble and entrepreneurial spirit of a biotech.

At Servier Pharmaceuticals we are committed to fostering an entrepreneurial, free-thinking environment focused on delivering meaningful improvements in patient care today and into the future. Our unique independence allows us to do just that.

We are a team of visionaries, discoverers and pioneers. We are guided by four core values: Dare to Innovate, Care, Commit to Succeed and Grow by Sharing.

Our ambition is to develop a mutual relationship of trust and inspiration where you can contribute your skills and talents, in an environment where you can grow and develop.

See below for current job openings:

  • Medical Science Operations Manager
  • Product Operations Project Manager
  • Senior Medical Science Liaisonr

To apply or for more information, email us with the following information:

  • Your Resume
  • Subject Line: Your Name, Job Opening you're interested in

email us


We are committed to fostering relationships that will allow us to make meaningful improvements in patient care. We look forward to connecting and collaborating with others who share our vision of bringing the promise of tomorrow to the patients we serve.

Corporate Headquarters
200 Pier Four Boulevard
Boston, MA 02210